Markets:

Overview

News

Currencies

International

Treasuries

Vir Biotechnology, Inc. - Common Stock (NQ:VIR)

11.46 -0.23 (-2.01%)

Delayed Quote Updated: 9:30 AM EDT, Oct 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vir Biotechnology, Inc. - Common Stock

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

November 17, 2021

Good morning, trader! We're halfway through the week and with that comes a look at the biggest pre-market stock movers for Wednesday!

Via InvestorPlace

25 Stocks Moving in Wednesday's Pre-Market Session ↗

November 17, 2021

Gainers 17 Education & Technology Group Inc. (NASDAQ: YQ) rose 283.5% to $3.16 in pre-market trading. 17 Education & Technology, earlier during the month, reported a $10...

Via Benzinga

GSK, Vir's Intramuscularly-Administered Sotrovimab Shows Efficacy At Par With IV Route In COVID-19 ↗

November 12, 2021

GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc (NASDAQ: VIR) have announced topline data from COMET-TAIL Phase 3 trial evaluating sotrovimab delivered...

Via Benzinga

The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares ↗

November 12, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus J&J to Separate Its Consumer Health Business Into a New Publicly Traded...

Via Benzinga

3 Vaccine Stocks With Big Opportunities Outside of COVID-19 ↗

November 11, 2021

For most of the past two years, all the focus has been on the coronavirus, but these biotechs have big plans to develop inoculations against other diseases, too.

Via The Motley Fool

Why Vir Biotechnology Stock Is Sliding Today ↗

November 05, 2021

Efficacy results for oral antivirals from Pfizer and Merck are weighing heavily on Vir today.

Via The Motley Fool

The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More ↗

November 08, 2021

Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out...

Via Benzinga

GlaxoSmithKline Drops Research On Otilimab In COVID-19 ↗

October 27, 2021

GlaxoSmithKline Plc (NYSE: GSK), in its Q3 earnings release, revealed that it is stopping the development of otilimab in COVID-19 in patients who are at least 70 years...

Via Benzinga

The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO ↗

November 04, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 25, 2021 ↗

October 25, 2021

Upgrades According to Wedbush, the prior rating for Regions Financial Corp (NYSE:

Via Benzinga

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗

October 31, 2021

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...

Via Benzinga

10 Biggest Price Target Changes For Monday ↗

October 25, 2021

Wells Fargo boosted Bank of America Corporation (NYSE:B...

Via Benzinga

GlaxoSmithKline: My Top Value Stock For The Week ↗

October 23, 2021

GSK, one of the biggest pharmaceuticals companies in the world, is seeing a lot of success with new drugs and plenty more in the pipeline. Better yet for would-be investors, the stock is still very...

Via Talk Markets

Moderna Slapped With Sell Rating Despite CDC Authorization For Covid Boosters ↗

October 22, 2021

The CDC authorized boosters from J&J, Moderna and a mix-and-match approach.

Via Investor's Business Daily

The Next Challenge For Covid Stocks Is Also A Cash Cow For These Companies ↗

October 15, 2021

Companies working on sorely needed Covid treatments are innovating to keep up.

Via Investor's Business Daily

AstraZeneca's COVID-19 Therapy Hits Goal In Phase 3 Trial ↗

October 11, 2021

AstraZeneca Plc (NASDAQ: AZN) released top-line data from the TACKLE Phase 3 trial in which its experimental COVID-19 drug has helped cut the risk of severe disease...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

October 06, 2021

Gainers Voyager Therapeutics (NASDAQ:VYGR) shares increased by 46.15% to $3.61 during Wednesday's pre-market session. The company's market cap stands at $136.9...

Via Benzinga

Tesla and Merck Give Investors Some Hope ↗

October 04, 2021

Friday’s rally appears to have lost its momentum over the weekend because stock futures are trading lower before Monday’s open. China’s troubled real estate...

Via Benzinga

54 Biggest Movers From Friday ↗

October 04, 2021

Check out these big penny stock gainers and losers Losers Spire Global, Inc.. (NYSE: SPIR) shares fell 43.3% to close at $7.10 on Friday. Spire Global, Inc....

Via Benzinga

Mid-Afternoon Market Update: Nasdaq Rises Over 100 Points; Biomerica Shares Spike Higher ↗

October 01, 2021

Toward the end of trading Friday, the Dow traded up 1.49% to 34,346.53 while the NASDAQ rose 0.75% to 14,556.92. The S&P also rose, gaining 1.18% to 4,358.52. The U.S. has the...

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Friday's Intraday Session ↗

October 01, 2021

Gainers Biomerica (NASDAQ:BMRA) stock moved upwards by 39.33% to $6.27 during Friday's regular session. As of 12:30 EST, Biomerica's stock is trading at a volume...

Via Benzinga

Merck Stock Surges Into Buy Zone As Covid Pill Reduces Risk Of Death, Hospitalization ↗

October 01, 2021

Merck said its Covid pill, molnupiravir, cut the risk of death and hospitalization by half.

Via Investor's Business Daily

Topics Stocks

Glaxo - Vir Biotech's COVID Treatment Approved In Japan ↗

September 27, 2021

Japan's health ministry expert committee has approved GlaxoSmithKline Plc (NYSE: GSK) - Vir Biotechnology Inc's (NASDAQ: VIR) sotrovimab, a COVID-19...

Via Benzinga

The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug ↗

September 30, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc. (...

Via Benzinga

Why Vir Biotechnology Stock Is Sinking This Week ↗

September 24, 2021

Shares fell after an analyst's downgrade.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For September 22, 2021 ↗

September 22, 2021

Upgrades Argus Research upgraded the previous rating for Simon Property Group Inc (NYSE:

Via Benzinga

Vir Biotechnology Earnings Perspective: Return On Capital Employed ↗

September 06, 2021

According to Benzinga Pro, during Q2, Vir Biotechnology (NASDAQ:VIR) earned $61.02 million, a 138.46% increase from the preceding quarter. Vir Biotechnology also posted a total of...

Via Benzinga

Now May Be the Big Moment for These 2 COVID Stocks ↗

September 02, 2021

Their products are seeing a surge in demand.

Via The Motley Fool

9 Health Care Stocks With Unusual Options Alerts In Today's Session ↗

August 23, 2021

This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges...

Via Benzinga

Vir Biotech-GSK's COVID-19 Treatment Wins Provisional Approval In Australia ↗

August 23, 2021

The Australian Therapeutic Goods Administration has granted provisional marketing authorization for Vir Biotechnology Inc's (NASDAQ: VIR) for sotrovimab,...

Via Benzinga

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.